Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC – Get Rating) have received an average recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $162.27.

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on iRhythm Technologies from $185.00 to $190.00 in a report on Thursday. BTIG Research upped their target price on shares of iRhythm Technologies from $155.00 to $178.00 and gave the company a "buy" rating in a research note on Friday, August 5th. Truist Financial dropped their price target on shares of iRhythm Technologies from $200.00 to $165.00 and set a "buy" rating on the stock in a research note on Thursday, June 16th. Canaccord Genuity Group upped their price objective on shares of iRhythm Technologies from $185.00 to $198.00 and gave the company a "buy" rating in a research report on Friday, September 2nd. Finally, Canaccord Genuity Group lifted their target price on iRhythm Technologies from $185.00 to $198.00 and gave the stock a "buy" rating in a research report on Friday, September 2nd.

Insider Transactions at iRhythm Technologies

In related news, CFO Douglas Devine sold 1,239 shares of the company's stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $108.90, for a total transaction of $134,927.10. Following the sale, the chief financial officer now directly owns 39,811 shares of the company's stock, valued at approximately $4,335,417.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO Douglas Devine sold 1,239 shares of the firm's stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $108.90, for a total transaction of $134,927.10. Following the transaction, the chief financial officer now directly owns 39,811 shares in the company, valued at $4,335,417.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel G. Wilson sold 1,428 shares of the firm's stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $108.93, for a total value of $155,552.04. Following the transaction, the executive vice president now owns 37,562 shares in the company, valued at $4,091,628.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,866 shares of company stock worth $1,459,508. 1.64% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On iRhythm Technologies

iRhythm Technologies Trading Down 5.2 %

Shares of IRTC stock opened at $122.73 on Friday. The company has a quick ratio of 3.84, a current ratio of 4.04 and a debt-to-equity ratio of 0.14. iRhythm Technologies has a fifty-two week low of $56.49 and a fifty-two week high of $169.54. The firm's 50 day moving average price is $150.09 and its two-hundred day moving average price is $138.70. The stock has a market cap of $3.69 billion, a price-to-earnings ratio of -27.77 and a beta of 1.51.

iRhythm Technologies (NASDAQ:IRTC – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.15. iRhythm Technologies had a negative net margin of 36.15% and a negative return on equity of 38.95%. The business had revenue of $102.10 million for the quarter, compared to analyst estimates of $100.51 million. During the same quarter in the previous year, the business posted ($0.59) EPS. The business's quarterly revenue was up 25.6% on a year-over-year basis. On average, analysts anticipate that iRhythm Technologies will post -3.06 EPS for the current year.

About iRhythm Technologies

(Get Rating)

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Recommended Stories

• Get a free copy of the StockNews.com research report on iRhythm Technologies (IRTC)
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
• Will Crowdstrike Get A Boost From Increased EPS Guidance?

Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.